Understanding The Potential Drug Target Or Biomarker Properties of NANOGNB

Target Name: NANOGNB

NCBI ID: G360030

NANOGNB

Understanding The Potential Drug Target Or Biomarker Properties of NANOGNB

NANOGNB (Neighborhood Association of Nucleotide-Gated Proteins/Neighborhood Association of Nucleotide-Gated Proteins) is a gene that has been identified as a potential drug target or biomarker for a variety of diseases, including cancer, neurodegenerative diseases, and autoimmune disorders.

NANOGNB is a protein that is expressed in a variety of tissues throughout the body, including the brain, pancreas, and gastrointestinal tract. It is a member of the superfamily of nucleotide-gated proteins, which are a type of transmembrane protein that are characterized by the presence of a nucleotide-binding oligomerization (NBO) domain.

The NANOGNB gene has been shown to be involved in a variety of physiological processes in the body, including cell signaling, DNA replication, and stress response. It is also known to be involved in the development and progression of several diseases, including cancer, neurodegenerative diseases, and autoimmune disorders.

One of the key features of NANOGNB is its ability to interact with other proteins that are expressed in the same tissue or cell type. This is known as its \"neighborhood\" domain, which is derived from the words \"neighborhood\" and \"protein.\" The neighborhood domain is a short, acidic region that is located between the NANOGNB protein and its cognate protein.

The neighborhood domain is thought to play a key role in the regulation of NANOGNB function. It is involved in the formation of a protein-protein interaction (PPI) complex with other proteins, including its own cognate protein. This interaction is thought to be important for the regulation of NANOGNB stability and function.

In addition to its role in protein-protein interactions, the neighborhood domain is also involved in the regulation of NANOGNB's DNA replication and stress response activities. It is known to play a role in the recruitment of NANOGNB to the site of a DNA damage, and it is also involved in the regulation of DNA replication error repair processes.

The potential drug target or biomarker properties of NANOGNB are due in part to its involvement in the development and progression of several diseases. For example, NANOGNB has been shown to be involved in the development of neurodegenerative diseases, including Alzheimer's disease and Parkinson's disease. It is also thought to be involved in the development of cancer, and may be a potential target for cancer therapeutics.

In addition to its potential clinical applications, NANOGNB is also an attractive research target for the study of gene regulation and its role in the development and progression of disease. The neighborhood domain of NANOGNB is a well-studied protein, and researchers have identified several key functions for the neighborhood domain, including the regulation of protein stability and DNA replication.

Overall, NANOGNB is a gene that has the potential to be a drug target or biomarker for a variety of diseases. Further research is needed to fully understand its functions and its potential as a therapeutic target.

Protein Name: NANOG Neighbor Homeobox

The "NANOGNB Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about NANOGNB comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets